PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.\', \'Division of Biostatistics, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.\', \'Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.\', \'Vaxcyte, Inc, Foster City, CA, USA.\', \'Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA. Hang.Xie@fda.hhs.gov.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41467-021-26803-w
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 34772941
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
?:title
  • SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all